Stocks › ATOS

ATOSSA THERAPEUTICS, INC.

ATOS·Nasdaq·United States United States·USD
$1.59
-0.16 (-8.86%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
ATOS
ATOSSA THERAPEUTICS, INC. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
ATOSS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of ATOS by members of U.S. Congress · 1 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Roger MarshallRoger MarshallHouse · R · KS ATOSATOSSA THERAPEUTICS, INC. · Stock Purchase
$1,001 - $15,000
Aug 6, 2018 Oct 25, 2017 Filing ↗

Whale Activity

Position changes in ATOS reported for 2026-09-30 by 40 institutional filers
Increased: 6New: 9Held: 14Decreased: 5Closed: 5No prior filing: 1
  • Increased6
  • New9
  • Held14
  • Decreased5
  • Closed5
  • No prior filing1
FilerSharesValueChange
VANGUARD CAPITAL MANAGEMENT LLC361.7K$705Kheld
BlackRock, Inc.168.6K$329Kincreased
RENAISSANCE TECHNOLOGIES LLC109.9K$214Kdecreased
GEODE CAPITAL MANAGEMENT, LLC95.6K$186Kincreased
VANGUARD FIDUCIARY TRUST CO52.6K$103Kheld
STATE STREET CORP39.8K$78Kheld
UBS Group AG30.5K$59Kdecreased
AMERIPRISE FINANCIAL INC27.4K$53K—
SUSQUEHANNA INTERNATIONAL GROUP, LLP21.5K$42Kincreased
NORTHERN TRUST CORP20.2K$39Kdecreased
MILLENNIUM MANAGEMENT LLC14.9K$29Kdecreased
MORGAN STANLEY12.3K$24Kheld

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by ATOS insiders, by quarter · Form 4
-20.0K-10.0K010.0K20.0K2025 Q1: 10.0K2025 Q12025 Q2: 11.2K2025 Q22025 Q3: 02025 Q32025 Q4: 02025 Q42026 Q1: 02026 Q12026 Q2: 02026 Q22026 Q3: 02026 Q32026 Q4: 02026 Q4

Recent Insider Transactions

49 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Steinhart Richard IDirector Grant / award +10.0K $0.00 $0 May 12, 2026 Form 4 ↗
Chen Shu-ChihDirector Grant / award +10.0K $0.00 $0 May 12, 2026 Form 4 ↗
Remmel H. LawrenceDirector Grant / award +10.0K $0.00 $0 May 12, 2026 Form 4 ↗
Finn JonathanDirector Grant / award +10.0K $0.00 $0 May 12, 2026 Form 4 ↗
Galli Stephen JDirector Grant / award +10.0K $0.00 $0 May 12, 2026 Form 4 ↗
Cigler TessaDirector Grant / award +10.0K $0.00 $0 May 12, 2026 Form 4 ↗
QUAY STEVEN CPresident & CEO · Director Grant / award +65.0K $0.00 $0 Mar 27, 2026 Form 4 ↗
Daniel Mark JamesChief Financial Officer Grant / award +63.0K $0.00 $0 Mar 26, 2026 Form 4 ↗
QUAY STEVEN CPresident & CEO · Director Grant / award Amended +331.7K $0.00 $0 Jan 20, 2026 Form 4 ↗
QUAY STEVEN CPresident & CEO · Director Grant / award +325.2K $0.00 $0 Jan 20, 2026 Form 4 ↗
QUAY STEVEN CPresident & CEO · Director Purchase +11.2K $0.88 $10K May 21, 2025 Form 4 ↗
Remmel H. LawrenceDirector Purchase +10.0K $0.70 $7K Mar 26, 2025 Form 4 ↗
Finn JonathanDirector Purchase +25.0K $1.77 $44K Apr 10, 2024 Form 4 ↗
WEAVER GREGORY LFormer EVP, CFO, & Director · Director Sale −50.0K $0.65 $33K Nov 15, 2023 Form 4 ↗
WEAVER GREGORY LEVP & CFO · Director Purchase +50.0K $0.97 $49K Jun 20, 2023 Form 4 ↗
WEAVER GREGORY LDirector Sale −107.5K $5.58 $600K Jul 2, 2021 Form 4 ↗
WEAVER GREGORY LDirector Tax withholding −57.1K $6.40 $365K Jul 2, 2021 Form 4 ↗
WEAVER GREGORY LDirector Option exercise +70.0K $1.70 $119K Jul 2, 2021 Form 4 ↗
WEAVER GREGORY LDirector Option exercise +45.0K $2.52 $113K Jul 2, 2021 Form 4 ↗
WEAVER GREGORY LDirector Option exercise +45.0K $2.38 $107K Jul 2, 2021 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding ATOS · SEC Form N-PORT
FundSharesValue% of fundAs of
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
256.1K$494K0.00%Jun 30, 2026
Columbia Small Cap Value Discovery Fund
COLUMBIA FUNDS SERIES TRUST I
201.4K$417K0.02%Jul 31, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
99.1K$191K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund
Fidelity Concord Street Trust
44.7K$112K0.00%Aug 31, 2026
Columbia Variable Portfolio - Small Cap Value Discovery Fund
COLUMBIA FUNDS VARIABLE INSURANCE TRUST
36.4K$70K0.02%Jun 30, 2026
iShares Micro-Cap ETF
iShares Trust
29.2K$56K0.00%Jun 30, 2026
Fidelity Total Market Index Fund
Fidelity Concord Street Trust
14.4K$36K0.00%Aug 31, 2026
Fidelity Series Total Market Index Fund
Fidelity Concord Street Trust
12.6K$32K0.00%Aug 31, 2026
U.S. SMALL CAP PORTFOLIO
DFA INVESTMENT DIMENSIONS GROUP INC
2,842$15K0.00%Apr 30, 2026
U.S. MICRO CAP PORTFOLIO
DFA INVESTMENT DIMENSIONS GROUP INC
2,450$13K0.00%Apr 30, 2026

Mutual funds and ETFs whose N-PORT filings list ATOS's shares (CUSIP 04962H704), each fund at its latest report since Apr 22, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings

No 13D/13G beneficial-ownership filings on record.

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming atossa therapeutics as client

No lobbying filings found naming ATOSSA THERAPEUTICS, INC. as the client.

  • DESIMONE CONSULTING, LLCATOSSA THERAPEUTICS, INC. · 2021 Q1 · MED$40K
    Filing ↗
  • DESIMONE CONSULTING, LLCATOSSA THERAPEUTICS, INC. · 2020 Q4 · MED$40K
    Filing ↗
  • DESIMONE CONSULTING, LLCATOSSA THERAPEUTICS, INC. · 2020 Q3 · MED$40K
    Filing ↗
  • DESIMONE CONSULTING, LLCATOSSA THERAPEUTICS, INC. · 2020 Q2 · MED$20K
    Filing ↗
  • DESIMONE CONSULTING, LLCATOSSA THERAPEUTICS, INC. · 2020 Q2 · MED—
    Filing ↗

Government Contracts

Federal awards to ATOSSA THERAPEUTICS, INC. · USAspending

No federal contract awards found for ATOSSA THERAPEUTICS, INC..

U.S. Patents

Recent USPTO applications naming ATOSSA THERAPEUTICS, INC.

No USPTO patent applications found for ATOSSA THERAPEUTICS, INC..

Annual Financials

From ATOS's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Operating income-$37.1M-$27.6M-$31.4M-$27.7M-$20.5M
Net income-$34.8M-$25.5M-$30.1M-$27.0M-$20.6M
Diluted EPS-$4.04-$3.04-$0.24-$0.21n/a
Operating cash flow-$29.8M-$21.0M-$20.9M-$20.8M-$16.5M
Cash and equivalents$41.3M$71.1M$88.5M$110.9M$136.4M
Total assets$47.6M$76.4M$96.3M$123.5M$141.3M
Total liabilities$8.3M$5.0M$5.2M$5.6M$3.1M
Shareholders' equity$39.4M$71.5M$91.0M$118.0M$138.1M

As ATOSSA THERAPEUTICS, INC. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 25, 2026 ↗

Stock Splits

Every split and reverse split in the price history
  • 1-for-15Reverse splitFeb 2, 2026
  • 1-for-12Reverse splitApr 20, 2018
  • 1-for-15Reverse splitAug 26, 2016

Split dates and ratios from the price history · Close Prices from Tiingo.com

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsNov 10, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 3.03, 8.01, 9.01Material agreement · Modification of rights · Other eventsOct 9, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsSep 29, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 9.01Reg FD disclosureSep 18, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsAug 7, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 9.01Material agreementJun 11, 2026
    EDGAR ↗
  • 8-K · Items 9.01May 8, 2026
    EDGAR ↗
  • 8-K · Items 5.07Shareholder voteMay 8, 2026
    EDGAR ↗

About ATOSSA THERAPEUTICS, INC.

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersSEATTLE, WA
IncorporatedDE
Former namesATOSSA GENETICS INC